X0306 4 2018-08-30 0 0001619087 SteadyMed Ltd. STDY 0001356227 RIGBY JONATHAN C/O STEADYMED THERAPEUTICS, INC. 2603 CAMINO RAMON, SUITE 350 SAN RAMON CA 94583 1 1 0 0 President and CEO Ordinary Shares 2018-08-30 4 S 0 41605 4.46 D 0 D Ordinary Shares 2018-08-30 4 S 0 4960 4.46 D 0 I By Spouse Stock Option (Rt to Buy) 3.61 2018-08-30 4 J 0 18515 0.00 D 2020-05-01 Ordinary Shares 18515 0 D Stock Option (Rt to Buy) 3.61 2018-08-30 4 J 0 145212 0.00 D 2021-07-07 Ordinary Shares 145212 0 D Stock Option (Rt to Buy) 5.84 2018-08-30 4 J 0 131451 0.00 D 2022-01-25 Ordinary Shares 131451 0 D Stock Option (Rt to Buy) 2.74 2018-08-30 4 J 0 63764 0.00 D 2026-06-17 Ordinary Shares 63764 0 D Stock Option (Rt to Buy) 3.65 2018-08-30 4 J 0 163394 0.00 D 2027-12-28 Ordinary Shares 163394 0 D Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time /s/ David W. Nassif, Attorney-In-Fact 2018-09-04